演題抄録

International Session(Poster)

開催概要
開催回
第51回・2013年・京都
 

The Anti-tumor Activity of Chinese Medical Prescription JC-001

演題番号 : ISP-2

[筆頭演者]
Meng-Hsien Chuang:1 
[共同演者]
Ming-Shiou Jan:2,3、Li-Jun Hsu:4、Jinghua Tsai Chang:1、Fung-Jou Lu:1

1:Institute of Medicine, Chung Shan Medical University, China、2:Department of Microbiology and Immunology, Chung Shan Medical University, China、3:Immunology and Rheumatology, Department of Internal Medicine, Chung-Shan Medical University Hospital, China、4:Department of Medical Laboratory Science and Technology, National Cheng Kung University, China

 

JC-001, a Chinese medical prescription that has been used for treating liver disease, but the significance in cancer treatment is still not characterized. In this study, we found a low cytotoxic effect affected on hepatoma cell lines including HepG2, Hep3B, HA-22T, SK-Hep-1 and Hepa 1-6 after JC-001 treatment for 96-hr. On the other hand, not direct cytotoxicity of JC-001 observed on normal human liver cell line THLE-3 under the same incubation condition. In a murine tumor model, Hepa 1-6 cells was inoculated into both T-cell deficient BALB/Nu and immunocompetent C57BL/6 mice, and after 7- to 10-day housing for tumor growth, the tumor-bearing mice were treated with JC-001 via oral administration. Our results indicated that the tumor growth could be inhibited in C57BL/6 mice, but not in BALB/Nu mice. By histopathologic analysis on tumor and normal tissue surround the tumor from C57BL/6, the immune cell infiltration in tumors was observed by H&E stain under JC-001 treated situation. Furthermore, the tumor obtained from JC-001 treated mice showed more severe necrosis than from JC-001-untreated mice. Our data suggest that JC-001 is a low cytotoxicity Chinese medical prescription, and it could suppress tumor growth significantly by immune regulation. This prescription has a great potential for clinical application in hepatoma therapy in the future.

前へ戻る